Shalby net profit slumps 4.18% to 18.3 crore in Q4
Total income jumps 2.11 per cent to 183.5 crore18-05-2023
18-05-2023
Q4FY23 Quarterly & FY23 Annual Result Announced for Shalby Ltd.
Healthcare Facilities company Shalby announced Q4FY23 & FY23 results: Consolidated Q4FY23: Revenues of Rs 2,082 million, growth of 25% YoY EBITDA of Rs 348 million, growth of 23% YoY Profit After Tax was Rs 139 million, growth of 37% YoY Occupied Bed during the quarter were 579, growth of 16% YoY In patient count (incl. Day Care) of 18,551, growth of 24% YoY Total Surgery count of 6,553, growth of 18% YoY Consolidated FY23: Consolidated Revenues of Rs 8,274 million, growth of 16% YoY Consolidated EBITDA of Rs 1,593 million, growth of 20% YoY Consolidated Profit After Tax was Rs 677 million, growth of 25% YoY In patient count (incl. Day Care) of 71,893, growth of 18% YoY Total Surgery count of 27,352, growth of 35% YoY ARPOB for full year was 34,842, growth of 11% YoY Net cash (after deducting debt) at group level stood at Rs 712 million in FY23 v/s Rs 475 mn in FY22 Board has declared dividend of Rs 1.20 per share (12% of face value) Mr. Shanay Shah, President said: “I am happy to report that our hospital business continued to deliver consistent performance in all key operational and financial parameters with surgery count and In-patient count (Incl day care) grew by 35% and 18% YoY respectively in full year FY23. Hospital revenue (Rs.7,274 mn) and EBITDA (Rs.1615 mn) grew by 11% and 13% YoY with robust EBITDA margin of 22% in full year FY23. ARPOB and ALOS were recorded at Rs.34,842 and 3.92 respectively in FY23 vis-à-vis Rs 31,347 and 4.55 in the previous year. Our core specialties such as Arthroplasty, Oncology, Cardiac Science, Orthopedic, Critical care & General Medicine, Neurology and Nephrology contributed 88% to the revenues respectively in FY23. International revenue of Rs. 104 million in FY23 grew by 144% YoY from FY22 whereby majority of the patients came from East African countries. Our homecare business also showed a strong performance with revenue grew by 38% YoY in FY23 at Rs.9.8 million, from FY22. The Shalby Academy vertical also showed an encouraging response with 2000+ students enrolled for various healthcare programs during FY23. Our Realized Return on Capital Employed from hospital business recorded at 16% in FY23 on an annualized basis v/s 14% in FY22. We have closed the quarter with a net cash balance of Rs. 712 million at the group level and are well positioned to fund our strategic growth plans. Shalby continued to add many milestones backed by clinical excellence and patient satisfaction and we feel proud to make a positive difference in people’s lives." Result PDF18-05-2023
Shalby Ltd - 540797 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor Presentation for the Quarter and year ended 31st March 2023.18-05-2023
Shalby Ltd - 540797 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Schedule of Investor conference call18-05-2023
Shalby Ltd - 540797 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release on audited consolidated financial results for FY 2022-2318-05-2023
Shalby Ltd - 540797 - Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s
Re-appointment of Statutory Auditors for second term of 5 years, subject to approval of members at ensuing annual general meeting18-05-2023
Shalby Ltd - 540797 - Disclosure U/R. 30(5) Of SEBI(Listing Obligation And Disclosure Requirements), Regulations 2015
Disclosure u/r. 30(5) of SEBI(Listing Obligation and Disclosure Requirements), Regulations 201518-05-2023
Shalby Ltd - 540797 - Appointment Of Mr. Amit Pathak, As Chief Financial Officer W.E.F. May 19, 2023
Appointment of Mr. Amit Pathak, as Chief Financial Officer w.e.f. May 19, 202318-05-2023
Shalby Ltd - 540797 - Announcement under Regulation 30 (LODR)-Resignation of Chief Financial Officer (CFO)
Resignation of CFO18-05-2023
Shalby Ltd - 540797 - Announcement under Regulation 30 (LODR)-Change in Management
Appointment of Mr. Ashok Bhatia and Mr. Vijay Kedia as Non-Executive and Independent Directors, subject to approval of members at the ensuing Annual General Meeting18-05-2023